We conducted a retrospective analysis of patients enrolled in the Hoosier Cancer Research Network LUN 14-179. Univariable Cox regression was performed to determine the variables associated with 3 end points: time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). Stage IIIA and longer duration of pembrolizumab might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.
- Adjuvant therapy
- Non–small-cell lung cancer
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cancer Research